# Faculty Position: Heavy Particle Radiobiology/DNA Damage Response and Repair Scientist — Mayo Clinic

- Location: Jacksonville, FL
- Posted: Aug 26, 2026
- Status: open (checked Nov 22, 2026)
- Apply (employer's site): https://fa-euwp-saasfaprod1.fa.ocs.oraclecloud.com/hcmUI/CandidateExperience/en/sites/jobsearch/job/386347
- Employer record: https://visajobs.io/company/mayo-clinic.md

## Sponsorship history
- Tier: Employer history only
- With this exact title: 0

## Description
Position Description
Mayo Clinic and Mayo Clinic Comprehensive Cancer Center in Florida invite applications for an open-rank faculty position for innovative and accomplished scientists focused on DNA damage repair and response pathways, particularly in the context of high linear energy transfer (LET) heavy particle therapies - including proton and carbon ion - in animal models and/or human clinical research studies and clinical trials. The successful recruit will have an unparalleled opportunity i to expand and lead rapidly expanding, innovative, and exciting programs in radiation biology and oncology.
In 2025, Mayo Clinic Florida completed initial construction of the Duan Family Integrated Oncology Building. A pioneering investment, representing the first carbon ion treatment facility in the Americas, the 225,000 square foot, $233 million building offers a range of options for individualized radiotherapy, including conventional X-ray therapy, and 360-degree proton ion therapy and carbon ion therapy, a powerful new option for highly resistant cancers. Heavy particle therapy - including next-generation proton beam therapy and carbon ion therapy - has the potential to transform treatment paradigms not only for rare, radioresistant cancers but also more-common malignancies. Whether heavy particle treatments may be used in early stage disease for effective cure is also under investigation. The center will launch proton beam therapy in early 2027, with carbon ion therapy available in early 2028. Through collaboration with a global technology and engineering company headquartered in Japan and other partners, Mayo Clinic will provide treatment capabilities, including photon, proton and carbon ion therapy, that are available nowhere else in the world. To enhance the benefits of heavy particle therapy delivery, Mayo Clinic is partnering with a software development company to create an advanced treatment adaptive planning system for photon, proton and carbon ion therapies. This system, not currently available for most patients receiving radiation therapy, reduces the radiation dose sent to healthy tissue and provides real-time online adaptive treatment planning.
We seek an exceptional investigator with expertise in investigating mechanisms of DNA damage induction and molecular responses including DNA repair pathway dependencies after exposures to photons, protons and heavy charged particles (such as carbon) used for radiotherapy to guide precision radiation oncology and therapeutic combinations. As carbon ions in particular may elicit neo-antigens and trigger local and systemic anti-cancer immune responses, there will be significant opportunities to collaborate with other physicians and scientists to dissect these mechanistic pathways and translate them to unique combinatorial therapeutic interventions. As such, successful candidates will play a central role in advancing a rapidly growing, multidisciplinary heavy particle program focused on discovery science, translational innovation, and clinical impact.
Strategic Role and Leadership Expectations
The DNA Damage Response Scientist will:
Characterize cellular and molecular responses to photon, proton, and heavy-ion radiation.
Identify DNA repair pathway choices and map DDR vulnerabilities that can be used for patient stratification or co-targeted with inhibitors or gene-editing strategies to enhance efficacy of radiotherapy.
Develop preclinical models to test synergy between radiotherapy and targeted therapy.
Have the opportunity to drive science in neo-antigen discovery and combination immunotherapy in the context of DNA damage and molecular and cellular pathways.
Provide mechanistic insights to support clinical translation of carbon-ion–based treatment programs, in animal system and in clinical research and clinical trials.
Collaborate with computational scientists to identify and model clinical vulnerabilities to charged particle exposures and develop radiation-response signatures.
Research Environment
Mayo Clinic Florida offers a highly collaborative and integrated academic medical center environment with expanding strengths in heavy particle therapy, cancer immunotherapy, regenerative medicine, and translational science.
Faculty benefit from:
State-of-the-art genome engineering and cell manufacturing infrastructure
Access to institutional core facilities including genomics, single-cell sequencing, proteomics, bioinformatics, and advanced imaging
Robust disease-focused centers supporting both oncology and non-oncology therapeutic innovation
Dedicated institutional support for regulatory strategy, clinical trial development, and commercialization pathways
Cross-campus collaboration opportunities with Mayo Clinic sites in Minnesota and Arizona
Why Choose Mayo Clinic Comprehensive Cancer Center?
With 440 members and >1500 aligned cancer physicians working in six Cancer Research Programs (Cancer Prevention, Survivorship & Control; Cancer Risk Assessment, Early Detection & Interception; Cancer Genomics, Signaling, & Metastasis; Cancer Immunology & Immunotherapeutics; Novel Therapeutics & Therapeutic Modalities; Advanced Clinical Trials and Translational Sciences) and 15 Disease Groups focused on clinical trials, MCCCC is a global leader and represents the pinnacle of cancer care, research and education and training. Every year, across its three enterprise sites (Rochester, Minnesota; Phoenix and Scottsdale, Arizona; and Jacksonville, Florida), MCCCC physicians provide expert cancer diagnosis and treatment to more than 150,000 unique patients from across the nation and the globe. MCCCC created one of the nation’s first National Cancer Institute (NCI)-Designated Cancer Center Research Programs focused on early cancer detection and interception: Cancer Risk Assessment, Early Detection, and Interception (REDI). The Center’s other five transdisciplinary research programs include Cancer Prevention, Control, and Survivorship; Cancer Genomics, Signaling, an

> History, not a promise: past H-1B filings do not mean an employer will sponsor you or a given role. Data: U.S. DOL OFLC LCA disclosure (FY2024–FY2026 for role counts, certified LCAs) and the USCIS H-1B Employer Data Hub. Not legal advice. Methodology: https://visajobs.io/methodology
